Sökning: onr:"swepub:oai:DiVA.org:liu-102497" >
Allogeneic stem cel...
-
Thiel, UTechnical University of Munich, Germany
(författare)
Allogeneic stem cell transplantation for patients with advanced rhabdomyosarcoma: a retrospective assessment
- Artikel/kapitelEngelska2013
Förlag, utgivningsår, omfång ...
-
2013-10-22
-
Cancer Research UK,2013
-
printrdacarrier
Nummerbeteckningar
-
LIBRIS-ID:oai:DiVA.org:liu-102497
-
https://urn.kb.se/resolve?urn=urn:nbn:se:liu:diva-102497URI
-
https://doi.org/10.1038/bjc.2013.630DOI
Kompletterande språkuppgifter
-
Språk:engelska
-
Sammanfattning på:engelska
Ingår i deldatabas
Klassifikation
-
Ämneskategori:ref swepub-contenttype
-
Ämneskategori:art swepub-publicationtype
Anmärkningar
-
Funding Agencies|Wilhelm Sander-Stiftung|2006.109.1|Else Kroner-Fresenius-Stiftung|P31/08//A123/07|BMBF (TranSarNet FK)|01GM087001GM1104B|Deutsche Forschungsgemeinschaft (DFG)|GR3728/2-1|AmGen and Chugai and the Deutsche Kinderkrebsstiftung|DKS 2010.07|
-
Background: Allogeneic haematopoietic stem cell transplantation (allo-SCT) may provide donor cytotoxic T cell-/NK cell-mediated disease control in patients with rhabdomyosarcoma (RMS). However, little is known about the prevalence of graft-vs-RMS effects and only a few case experiences have been reported. less thanbrgreater than less thanbrgreater thanMethods: We evaluated allo-SCT outcomes of 30 European Group for Blood and Marrow Transplantation (EBMT)-registered patients with advanced RMS regarding toxicity, progression-free survival (PFS) and overall survival (OS) after allo-SCT. Twenty patients were conditioned with reduced intensity and ten with high-dose chemotherapy. Twenty-three patients were transplanted with HLA-matched and seven with HLA-mismatched grafts. Three patients additionally received donor lymphocyte infusions (DLIs). Median follow-up was 9 months. less thanbrgreater than less thanbrgreater thanResults: Three-year OS was 20% (s. e.+/- 8%) with a median survival time of 12 months. Cumulative risk of progression was 67% (s. e.+/- 10%) and 11% (s. e.+/- 6%) for death of complications. Thirteen patients developed acute graft-vs-host disease (GvHD) and five developed chronic GvHD. Eighteen patients died of disease and four of complications. Eight patients survived in complete remission (CR) (median: 44 months). No patients with residual disease before allo-SCT were converted to CR. less thanbrgreater than less thanbrgreater thanConclusion: The use of allo-SCT in patients with advanced RMS is currently experimental. In a subset of patients, it may constitute a valuable approach for consolidating CR, but this needs to be validated in prospective trials.
Ämnesord och genrebeteckningar
-
rhabdomyosarcoma
-
allogeneic haematopoietic stem cell transplantation
-
graft-vs-tumour effect
-
reduced intensity conditioning
-
myeloablative conditioning
-
donor lymphocyte infusion
-
MEDICINE
-
MEDICIN
Biuppslag (personer, institutioner, konferenser, titlar ...)
-
Koscielniak, EKlinikum Stuttgart, Germany
(författare)
-
Blaeschke, FTechnical University of Munich, Germany
(författare)
-
Grunewald, T G P.Technical University of Munich, Germany
(författare)
-
Badoglio, MHop St Antoine, France
(författare)
-
Diaz, M A.Hospital Infantil University of Nino Jesus, Spain
(författare)
-
Paillard, CCHU Clermont Ferrand, France
(författare)
-
Prete, AOsped S Orsola Malpighi, Italy
(författare)
-
Ussowicz, MWroclaw Medical University, Poland
(författare)
-
Lang, PUniversity of Childrens Hospital, Germany
(författare)
-
Fagioli, FRegina Margherita Childrens Hospital, Italy
(författare)
-
Lutz, PHop Hautepierre, France
(författare)
-
Ehninger, GUniversity Hospital Carl Gustav Carus, Germany
(författare)
-
Schneider, PRouen University Hospital, France
(författare)
-
Santucci, AUniversity of Perugia, Italy
(författare)
-
Bader, PGoethe University of Frankfurt, Germany
(författare)
-
Gruhn, BJena University Hospital, Germany
(författare)
-
Faraci, MG Gaslini Childrens Research Institute, Italy
(författare)
-
Antunovic, PetarLinköpings universitet,Institutionen för klinisk och experimentell medicin,Hälsouniversitetet(Swepub:liu)petan27
(författare)
-
Styczynski, JColl Medical UMK, Poland
(författare)
-
Krueger, W H.Ernst Moritz Arndt University of Greifswald, Germany
(författare)
-
Castagna, LIst Clin Humanitas, Italy
(författare)
-
Rohrlich, PUniversity of Franche Comte, France
(författare)
-
Ouachee-Chardin, MHop Robert Debre, France
(författare)
-
Salmon, ACHU Nancy Brabois, France
(författare)
-
Peters, CSt Anna Childrens Hospital, Austria
(författare)
-
Bregni, MOsped Circolo, Italy
(författare)
-
Burdach, STechnical University of Munich, Germany
(författare)
-
Technical University of Munich, GermanyKlinikum Stuttgart, Germany
(creator_code:org_t)
Sammanhörande titlar
-
Ingår i:British Journal of Cancer: Cancer Research UK109:10, s. 2523-25320007-09201532-1827
Internetlänk
Hitta via bibliotek
Till lärosätets databas
- Av författaren/redakt...
-
Thiel, U
-
Koscielniak, E
-
Blaeschke, F
-
Grunewald, T G P ...
-
Badoglio, M
-
Diaz, M A.
-
visa fler...
-
Paillard, C
-
Prete, A
-
Ussowicz, M
-
Lang, P
-
Fagioli, F
-
Lutz, P
-
Ehninger, G
-
Schneider, P
-
Santucci, A
-
Bader, P
-
Gruhn, B
-
Faraci, M
-
Antunovic, Petar
-
Styczynski, J
-
Krueger, W H.
-
Castagna, L
-
Rohrlich, P
-
Ouachee-Chardin, ...
-
Salmon, A
-
Peters, C
-
Bregni, M
-
Burdach, S
-
visa färre...
- Artiklar i publikationen
-
British Journal ...
- Av lärosätet
-
Linköpings universitet